 AUSTIN, Texas, April 22, 2021 PRNewswire -- Natera, Inc. NASDAQ: NTRA, a pioneer and a global leader in cell-free DNA testing, receives pathway to future coverage for the Prospera donor-derived, cell-free DNA dd-cfDNA test to determine transplant rejection status in multiple organs. Today, the Centers for Medicare Medicaid Services CMS Molecular Diagnostics Program MoLDX published a future effective local coverage determination LCD that identifies and establishes this pathway to coverage in a broad range of solid organ transplants. 